• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

64-slice CTA tops SPECT in coronary disease patients

Article

Sixty-four-slice CT angiography could become the imaging study of choice to rule out cardiac catheterization in patients with an intermediate risk of coronary artery disease.

Sixty-four-slice CT angiography could become the imaging study of choice to rule out cardiac catheterization in patients with an intermediate risk of coronary artery disease.

Dr. Tamar Gaspar and colleagues at Carmel Medical Center in Haifa, Israel, reviewed retrospective data from 75 symptomatic patients who underwent 64-slice CTA and SPECT. They reported at the 2006 RSNA meeting that CTA identified significant stenosis in one-third of patients and excluded it in two-thirds of patients who showed grade 1 mild reversible perfusion defects on SPECT.

"If we can show normal coronaries on CT and take into account the high negative predictive value of CT for CAD, we won't have to refer these patients for invasive angiography," Gaspar said.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.